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Abstract  
Introduction: No comprehensive reports have been published on epidemiological status of Rhinocerebral zygomycosis infections and its outcome in our population, Hence, the current study came to address 
epidemiological characteristics as well as clinical outcome of patients with Rhinocerebral zygomycosis infection referred to a referral hospital in Iran. Methods: This retrospective study was performed at the Rasoul-
e-Akram hospital, an 800-bed tertiary care teaching hospital in Tehran, Iran. The pathology recorded charts were reviewed to identify all cases of Rhinocerebral zygomycosis from patients admitted between April 
2007 and March 2014. A diagnosis of Rhinocerebral zygomycosis was based on histopathological assessments. Results: Sixty four patients with Rhinocerebral zygomycosis were assessed. The mean age of the 
patients was 46.07 ± 22.59 years and 51.6% were female. Among those, 67.2% were diabetic, 26.6% were hypertensive and 29.7% had history of cancer. Different sinuses were infected in 73.4% of the patients. 
Out of all the patients 26.6% underwent surgical procedures and 17.2% were controlled medically. Extensive debridement was carried out in 40.6%. Neutropenia (<1500 cell/ µl) was revealed in 12.5%. In-hospital 
mortality rate was 35.9% and prolonged hospital stay (> 14 days) was found in 60.9%. According to the Multivariable logistic regression analysis, the main predictors of in-hospital mortality included female gender, 
advanced age, the presence of sinus infection, and neutropenia, while higher dosages of amphotericin administered had a protective role in preventing early mortality. In a similar Multivariate model, history of 
cancer could predict prolonged hospital stay, whereas using higher dose of amphotericin could lead to shortening length of hospital stay. Conclusion: There is no difference in demographic characteristics between 
our patients with Rhinocerebral zygomycosis and other nations. The presence of diabetes mellitus is closely associated with the presence of this infection. Sinus involvement is very common in those with 
Rhinocerebral zygomycosis leading to high mortality and morbidity. Besides female gender, advanced age, and presence of neutropenia was a major risk factor for increasing early mortality. The use of higher doses 
of antifungal treatment such as amphotericin can prevent both mortality and prolonged hospital stay. The cancer patients may need longer hospital stay because of needing comprehensive in-hospital treatment. 
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Introduction 
 
Zygomycosis refers to infectious disease variants caused by 
Mucorales fungi species [1]. It may occur in progressive underlying 
risk profile patients such as immunosuppression, diabetic 
ketoacidosis, malignancies, extreme malnutrition, any conditions led 
to iron overload, burns, and trauma. Zygomycosis has a life-
threatening nature with multi-organ involvements such as 
cutaneous, pulmonary, and even neurologic invasions [2]. Thus, 
proper management and treatment of this multi-infection needs 
early detection of underlying risk factors along with medical and 
even surgical aggressive therapies. However, misdiagnosing 
identifiable risk factors is now a major problematic issue to improve 
disease progression and outcome [3,4]. Moreover, because of 
identified different routes of infection such as inhalation of conidia, 
gastrointestinal ingestion (among malnourished patients), non-
sterile tape and contaminated wooden splints, traumatic inoculation, 
and even via natural disasters [5-9], the problem is compounded for 
disease control and treatment. Descriptions of zygomycosis appear 
to be increasing, perhaps given higher numbers of persons at risk 
[10]. Epidemiologically, the infection by zygomycosis has a 
worldwide distribution with no known gender, age, or interracial 
preferences; however some institutional studies have shown a 
gender tendency with a male-to-female ratio of 3:1 [11]. Regarding 
disease prognosis, the presence of some serious comorbidities and 
needing aggressive coordinated treatment strategies may potentially 
affect prognosis, however despite all efforts to identify disease risk 
factors as well as to control disease progress, zygomycosis may 
carry a mortality rate of 50-85% mostly due to its serious 
consequences including rhinocerebral and pulmonary events [12-
14]. Unfortunately, no comprehensive reports have been published 
on epidemiological status of mucormycosis infections and its 
outcome in our population from 2007, Hence, the current study 
came to address epidemiological characteristics as well as clinical 
outcome of patients with mucormycosis infection referred to a 
referral hospital in Iran. 
  
  
Methods 
 
This retrospective study was performed at the Rasoul-e-Akram 
hospital, an 800-bed tertiary care teaching hospital in Tehran, Iran. 
The pathology recorded charts were reviewed to identify all cases of 
zygomycosis from patients admitted between April 2007 and March 
2014. Patients were included in the study if they met the criteria for 
proven invasive Rhinocerebral zygomycosis based on the revised 
definitions of invasive fungal disease of the European Organization 
for Research and Treatment of Cancer/Mycosis Study Group 
(EORTC/MSG) [15]. In total, 91 patients were identified that among 
them, 16 were excluded because of discharge against medical 
advice. The cases that were diagnosed on an outpatient basis or on 
the day of surgery and were not admitted to either hospital were 
also excluded. Data was collected on patients´ demographics, 
underlying conditions, concomitant immunosuppressive medications, 
laboratory data, radiologic findings, clinical features, antifungal 
treatment, surgical procedures, and outcomes. A diagnosis of 
Rhinocerebral zygomycosis was based on histopathological 
demonstration of broad, ribbon-like, wide-angled branching, non-
septate hyphae even in the absence of positive cultures, and 
accompanying tissue invasion by fungal hyphae [16,17]. The 
zygomycosis genus was determined by morphological examination 
of conidia, hyphae, and whole colonies.The study endpoint was first 
to assess in-hospital mortality and length of hospital stay and 
second was to determine main predictors of mortality and prolonged 
hospital stay in the patients. Results were presented as mean ± 
standard deviation (SD) for quantitative variables and were 
summarized by frequency (percentage) for categorical variables. 
Continuous variables were compared using t test or Mann-Whitney 
U test whenever the data did not appear to have normal distribution 
or when the assumption of equal variances was violated across the 
study groups. Categorical variables were, on the other hand, 
compared using chi-square test. The multivariable regression 
models were applied to determine indicators of disease outcome. 
For the statistical analysis, the statistical software SPSS version 16.0 
for windows (SPSS Inc., Chicago, IL) was used. P values of 0.05 or 
less were considered statistically significant. 
  
  
Results 
 
In total, 64 patients with Rhinocerebral zygomycosis were assessed. 
The mean age of the patients was 46.07 ± 22.59 years (ranged 4 to 
87 years) from which 51.6% were female. The mean age of 
affected men was similar to diseased women (45.89 ± 26.36 years 
versus 46.24 ± 18.80 years, p = 0.950). The overall prevalence of 
malignant conditions was 29.7%, 67.2% were diabetic, and 26.6% 
were hypertensive. The average dose of amphotericin in 
Page number not for citation purposes 3 
administered patients was 2135.64 ± 1870.91 mg. Different sinuses 
were infected in 73.4%, 26.6% underwent surgical procedures once 
and 56.2% underwent these procedures more than once, and 
17.2% were controlled medically (Figure 1). Functional endoscopic 
sinus surgery (FESS) was also done on 53.1% of patients. Eye 
enucleating was considered for 18.8% of cases. Regarding 
diagnostic approaches, pathological assessment was planned for 
85.9% and 25.0% were also assessed by endoscopy. Extensive 
debridement was carried out in 40.6% as a surgical procedure. The 
mean WBC count of the patients was 7947.60 ± 5446.86 cells per 
microliter (µl) of blood that neutropenia (<1500 cell/ µl) was 
revealed in 12.5%. In total, in-hospital mortality rate was 35.9%. 
The mean length of hospital stay was 26.94 ± 24.70 days that 
prolonged hospital stay (> 14 days) was found in 60.9% of the 
patients. According to the Multivariable logistic regression analysis 
(Table 1), the main predictors of in-hospital mortality included 
female gender (OR = 5.263, P = 0.002), advanced age (OR = 
1.063, P = 0.001), the presence of sinus infection (OR = 4.836, P = 
0.018), and neutropenia (OR = 31.250, P = 0.003), while higher 
dosages of amphotericin deoxycholate administered had a 
protective role in preventing early mortality (OR = 0.825, P = 
0.025). In a similar Multivariate model (Table 2), history of cancer 
could predict prolonged hospital stay (OR = 8.413, P = 0.043), 
whereas using higher dose of amphotericin could lead to shortening 
length of hospital stay (OR = 0.998, P < 0.001). 
  
  
Discussion 
 
As the first results and regarding demographic characteristics of our 
patients who suffered Rhinocerebral zygomycosis, we showed the 
prevalence of disease in an age wide spectrum from childhood to 
old adulthood. Also, men and women were similarly affected by this 
infection. Among underlying risk profiles, high prevalence of 
diabetes mellitus was revealed among patients that was shown in 
about two-third of them. Epidemiological studies showed high 
prevalence of diabetes mellitus in the patients in both developed 
and developing nations, however some clear differences were also 
revealed in the epidemiological aspects of disease between the 
nations that in developed countries, the disease remains uncommon 
and mostly occur in patients with diabetes mellitus and 
hematological malignancies, while in developing countries, 
zygormycosis has a sporadic pattern closely related to uncontrolled 
diabetes or trauma [18-20]. It seems that the relationship between 
high incidence rate of zygomycosis and diabetes is mainly influenced 
by uncontrolled situation of diabetes or occurring ketoacidosis as a 
serious predisposing factor for this infection. In total, reviewing the 
literature demonstrated the risky role of diabetes mellitus in 36% to 
88% of patients [20-25].In contrast, controlling diabetes, proper 
management of ketoacidosis and the use of statins as a main 
treatment protocols for metabolic syndrome could effectively reduce 
the incidence of zygomycosis [26-28]. Sinuses involvement is a 
common clinical manifestations affecting disease poor prognosis. 
This complication commonly appears as rhinocerebral 
mucormycosis, that is manifested by either sinusitis or periorbital 
cellulitis [29]. If untreated, sinusitis can spread from the sinuses and 
extend into the neighboring tissues such as orbit or orbital muscular 
complex leading to potential visual complications or may extend into 
the mouth and produce painful, necrotic ulcerations of the hard 
palate [30]. Another serious complication can be the spreading 
infection from sinus posteriorly to central nervous system and 
leading to cerebral vascular invasion and cerebral infarction, a 
serious cause for increasing disease-related mortality [31]. In our 
observation, 73.4% of patients suffered sinuses infections that 
mostly underwent invasive surgical procedure to prevent its 
progression. More importantly, the presence of sinusitis has been 
identified as an important predicting factor for early mortality in 
these patients leading to4.8 times more risk for mortality. 
  
We saw an early mortality of 35% for affected patients with 
Rhinocerebral zygomycosis that seems to be considerably high 
despite performing curative management in our center. Naturally, 
the early and long-term mortality following Rhinocerebral 
zygomycosis is strongly associated with the presence of underlying 
comorbidities. It has been shown that the overall mortality of 
pulmonary mucormycosis is approximately 50 to 70% [32,33]. 
Cutaneous and subcutaneous disease may lead to necrotizing 
fasciitis, which has a mortality approaching 80% [34,35]. The 
mortality associated with dissemination to the brain approaches 
100% [36]. In this regard, managing disease by proper antifungal 
agents leads to considerably decrease in mortality. It has been 
indicated that in cases with rhinocerebral mucormycosis, the 
mortality is about 70% in cases treated with antifungal agents alone 
versus 14% in cases treated with antifungal agents plus surgery 
[37,38]. Similarly, in a combined series of rhinocerebral, cutaneous, 
and pulmonary mucormycosis, 65% of patients treated with surgery 
plus antifungal agents survived the infection, compared to none of 
the patients treated with antifungal agents alone [39]. Thus, the 
death rate is directly associated with whether the patients were 
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managed medically or surgically. In our study, regardless of the 
type of comorbidity or treatment approach, high early mortality was 
reported following Rhinocerebral zygomycosis infection. However, as 
shown in our multivariable analysis, administrating antifungal 
treatment by high dose amphotericin, not only reduced in-hospital 
mortality, but also shortened hospital stay. However, it seems that 
the rate obtained for early mortality is notably high requiring deep 
assessment of its causes among our population. 
  
Two underlying conditions including history of cancer and presence 
of neutropenia can adversely affect outcome of Rhinocerebral 
zygomycosis as shown in our analysis. It has been clearly shown 
that the overall mortality rate for Rhinocerebral zygomycosis 
remains higher than 50%, and it approaches 100% among patients 
with persistent neutropenia [32,40]. In fact, the neutrophils are 
critical for inhibiting fungal spore proliferation and thus decrease in 
neutrophil count can predispose the patients to progressive 
Rhinocerebral zygomycosis. The risky role of neutropenia is more 
prominent in patients with malignancies especially hematological 
cancers with immunosuppressive patterns. 
  
  
Conclusion 
 
In summary, comparing our results with data previously reported in 
the literature shows similarities in demographic distribution of 
Rhinocerebral zygomycosis in our population. Among common 
comorbidities, the presence of diabetes mellitus is closely associated 
with the presence of this infection because more than two-third of 
affected patients with this infection are diabetics. Sinus involvement 
is very common in those with Rhinocerebral zygomycosis even in 
early stages of disease leading to high mortality and morbidity in 
the patients needing invasive surgical treatments. Besides female 
gender, advanced age, and presence of neutropenia (an indicator 
for immunosuppression) act as a major risk factor for increasing 
early mortality, the use of antifungal treatment such as high dose 
amphotericin can prevent both mortality and prolonged hospital 
stay. The cancer patients may need longer hospital stay because of 
needing comprehensive in-hospital treatments. 
 
 
 
What is known about this topic 
 Presence of diabetes mellitus is closely associated with 
rhinocerebral zygomycosis; 
 Neutropenia is a risk factor for early mortality in patients 
with rhinocerebral zygomycosis 
 
What this study adds 
 High dose amphotericin can reduce both mortality and 
prolonged hospital stay in patients with rhinocerebral 
zygomycosis; 
 Cancer patients need longer hospital stay for treatment of 
rhinocerebral zygomycosis 
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Table 1: Main predictors of in-hospital mortality 
Variable B S.E. Wald p-value OR 
95.0% CI for OR 
Lower Upper 
Female gender 1.662 .544 9.338 0.002 5.263 1.815 15.385 
Age 0.060 .018 11.099 0.001 1.063 1.026 1.101 
Diabetes -0.083 .980 0.007 0.932 0.920 0.135 6.283 
Hypertension -0.107 .484 0.049 0.825 0.898 0.348 2.319 
Amphotericin use 0.226 0.568 5.021 0.025 0.825 0.295 0.979 
Sinus infection 1.576 1.665 5.610 0.018 4.836 1.312 17.822 
Neutropenia -3.451 1.157 8.898 0.003 31.250 3.268 333.33 
Cancer 0.036 0.662 0.003 0.956 1.037 0.284 3.794 
Constant 7.912 2.392 10.944 0.001 2.730 
  
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Main predictors of prolonged hospital stay (LOS > 14 days) 
Variable B S.E. Wald p-value OR 
95.0% CI for OR 
Lower Upper 
Female gender -1.116 0.656 2.888 .089 0.328 0.091 1.186 
Age 0.034 0.020 2.846 .092 1.035 0.995 1.076 
Diabetes 0.324 1.138 0.081 .776 1.383 0.149 12.880 
Hypertension 0.778 0.734 1.123 .289 2.178 0.516 9.184 
Amphotericin use -0.002 0.000 22.696 .000 0.998 0.998 0.999 
Sinus infection 1.239 0.800 2.399 .121 3.453 0.720 16.571 
Neutropenia 0.258 1.056 0.060 .807 1.294 0.163 10.250 
Cancer 2.130 1.052 4.096 .043 8.413 1.070 66.169 
Constant -1.782 2.418 0.543 .461 0.168 
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Figure 1: Treatment approach in patients with sinus involvement related to mucormycosis 
 
